Anecortave

Drug Profile

Anecortave

Alternative Names: AL 3789; Anacortave; Anecortave acetate; Anecortave sodium; Retaane

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Alcon
  • Class Eye disorder therapies; Pregnadienediols; Small molecules
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Age-related macular degeneration
  • Discontinued Eye disorders; Glaucoma; Hereditary haemorrhagic telangiectasia

Most Recent Events

  • 26 Aug 2010 Alcon has been acquired by Novartis
  • 03 Jul 2009 Discontinued - Phase-II/III for Glaucoma in USA (Ophthalmic)
  • 12 Jul 2008 Discontinued - Phase-III for Age-related macular degeneration in India (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top